From July 16 to 18, 2026, the 34th Annual Meeting of the Japanese Cardiovascular Intervention Therapeutics (CVIT 2026) was successfully held at Tokyo International Forum. The conference brought together top clinical specialists, researchers and leading industry players worldwide to discuss cutting-edge advances and future trends in minimally invasive interventional diagnosis and treatment.

With years of in-depth expertise in the vascular intervention sector, Kossel Medtech (Suzhou) Co., Ltd. showcased its flagship coronary products at the exhibition, fully demonstrating its technological heritage and innovative strengths in precise vascular interventional treatment. Driven by continuous technological innovation and rigorous quality control, Kossel’s PTCA balloon, NC PTCA balloon and inflation device have obtained PMDA approval in Japan. Established market channels are in place, and multiple products have been adopted for clinical use in numerous hospitals, earning solid market recognition.

Kossel’s booth drew steady crowds throughout the event. The team conducted in-depth market engagement targeting Japan and hosted dedicated discussions with more than 20 Japanese clinicians. Exchanges centered on practical clinical operation details of interventional devices, directions for technological upgrades and Japanese market access requirements, alongside pragmatic discussions on regional promotion strategies. These conversations accurately captured the unique clinical demands of the Japanese market, laying a solid foundation for subsequent product registration, clinical adoption and customized R&D in Japan.

Kossel’s journey at CVIT 2026 has concluded successfully. Moving forward, Kossel Medtech will continue to expand its footprint in Japan, accelerate overseas certification of new products, enrich and optimize its product portfolio, and empower global clinical practice with high-quality vascular interventional medical devices and professional services.